{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:49:48Z","timestamp":1746085788871},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Orthop Trauma Surg"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00402-017-2697-8","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T08:56:12Z","timestamp":1493024172000},"page":"797-803","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A comparison of apixaban and dabigatran etexilate for thromboprophylaxis following hip and knee replacement surgery"],"prefix":"10.1007","volume":"137","author":[{"given":"Adriane","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.7326\/0003-4819-159-4-201308200-00008","volume":"159","author":"SS Adam","year":"2013","unstructured":"Adam SS, McDuffie JR, Lachiewicz PF, Ortel TL, Williams JW Jr (2013) Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement. Ann Intern Med 159:275\u2013284","journal-title":"Ann Intern Med"},{"key":"2697_CR2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5312\/wjo.v5.i3.188","volume":"5","author":"GB Aikens","year":"2014","unstructured":"Aikens GB, Osmundson JR, Rivey MP (2014) New oral pharmacotherapeutic agents for venous thrombosis prophylaxis after total hip arthroplasty. World J Orthop. 5:188\u2013203","journal-title":"World J Orthop."},{"key":"2697_CR3","first-page":"897","volume":"19","author":"S Bonarelli","year":"2015","unstructured":"Bonarelli S, Bacchin MR, Frugiuele I, Feoli MA (2015) Dabigatran etexilate and LMWH for the prevention of thromboembolism in 532 patients undergoing hip surgery. Eur Rev Med Pharmacol Sci. 19:897\u2013903","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"2697_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3810\/hp.2012.04.973","volume":"40","author":"S Deitelzweig","year":"2012","unstructured":"Deitelzweig S (2012) Preventing venous thrombotic events after total hip arthroplasty: new developments in clinical practice. Hosp Pract 40:79\u201387","journal-title":"Hosp Pract"},{"key":"2697_CR5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/ATVBAHA.114.303400","volume":"35","author":"C Messerschmidt","year":"2015","unstructured":"Messerschmidt C, Friedman RJ (2015) Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Trhomb Vasc Biol. 35:771\u2013778","journal-title":"Arterioscler Trhomb Vasc Biol."},{"key":"2697_CR6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2016.05.001","volume":"30","author":"LM Kwong","year":"2016","unstructured":"Kwong LM, Kimball JA (2016) Postorthopedic surgery joint replacement surgery venous thromboembolism prophylaxis. Hematol Oncol Clin North Am 30:1007\u20131018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2697_CR7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.thromres.2015.10.009","volume":"136","author":"W Feng","year":"2015","unstructured":"Feng W, Wu Km Liu Z, Kong G, Deng Z, Chen S, Wu Y, Chen M, Liu S, Wang H (2015) Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip of knee arthroplasty: systematic review, traditional meta-analysis, dose-response meta-analysis and network analysis. Thromb Res 136:1133\u20131144","journal-title":"Thromb Res"},{"key":"2697_CR8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1302\/0301-620X.96B1.31569","volume":"96-B","author":"BV Bloch","year":"2014","unstructured":"Bloch BV, Patel V, Best AJ (2014) Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. Bone Joint J 96-B:122\u2013126","journal-title":"Bone Joint J"},{"key":"2697_CR9","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/HIP.2011.8842","volume":"21","author":"SK Gill","year":"2011","unstructured":"Gill SK, Theodorides A, Smith N, Maguire E, Whitehouse SL, Rigby MC, Ivory JP (2011) Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis. Hip Int. 21:678\u2013683","journal-title":"Hip Int."},{"key":"2697_CR10","first-page":"1","volume-title":"Fachinformation Pradaxa\u00ae 110\u00a0mg Hartkapseln","author":"Boehringer Ingelheim","year":"2014","unstructured":"Ingelheim Boehringer (2014) Fachinformation Pradaxa\u00ae 110\u00a0mg Hartkapseln. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, pp 1\u201319"},{"key":"2697_CR11","first-page":"1","volume-title":"Prescribing information Eliquis\u00ae 2,5 mg","author":"Bristol-Myers Squibb, Pfizer","year":"2014","unstructured":"Bristol-Myers Squibb, Pfizer (2014) Prescribing information Eliquis\u00ae 2,5 mg. Bristol-M yers Squibb GmbH & Co, KG aA, M\u00fcnchen, pp 1\u201312"},{"key":"2697_CR12","first-page":"224","volume":"51","author":"S Nadler","year":"1962","unstructured":"Nadler S, Hidalgo J, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51:224\u2013232","journal-title":"Surgery"},{"key":"2697_CR13","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1185\/03007999609115227","volume":"13","author":"F Mercuriali","year":"1996","unstructured":"Mercuriali F, Intaglietta M (1996) Proposal of an algorithm to help the choice of the best transfusion strategy. Curr Med Res Opin 13:465\u2013478","journal-title":"Curr Med Res Opin"},{"key":"2697_CR14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00132-010-1651-z","volume":"39","author":"RM Aliyev","year":"2010","unstructured":"Aliyev RM (2010) Total hip replacement using the Staffelstein score: outcome of inpatient rehabilitation. Orthopade. 39:1163\u20131170","journal-title":"Orthopade."},{"key":"2697_CR15","first-page":"37","volume":"11","author":"A S\u0142upik","year":"2009","unstructured":"S\u0142upik A, Bia\u0142oszewski D (2009) A comparative analysis of the clinical utility of the Staffelstein-score and the hospital for special surgery knee score (HSS) in monitoring physiotherapy of total knee replacement patients\u2014preliminary study. Orthop Traumatol Rehabil 11:37\u201345","journal-title":"Orthop Traumatol Rehabil"},{"key":"2697_CR16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00059-012-3616-y","volume":"37","author":"CE Dempfle","year":"2012","unstructured":"Dempfle CE (2012) Pharmocology of the new oral anticoagulants. Herz. 37:362\u2013369","journal-title":"Herz."},{"key":"2697_CR17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/nyas.12567","volume":"1329","author":"MS Hanna","year":"2014","unstructured":"Hanna MS, Mohan P, Knabb R (2014) Annals of the New York Academy of Sciences. Ann N Y Acad Sci 1329:93\u2013106","journal-title":"Ann N Y Acad Sci"},{"key":"2697_CR18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00108-010-2725-z","volume":"51","author":"H V\u00f6ller","year":"2010","unstructured":"V\u00f6ller H, Alban S, Westermann D (2010) New oral anticoagulants: better than Vitamin K-antogonists? Internist. 51:1571\u20131581","journal-title":"Internist."},{"key":"2697_CR19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","volume":"26","author":"DM Monroe","year":"2006","unstructured":"Monroe DM, Hoffman M (2006) What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26:41\u201348","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl-1","key":"2697_CR20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","volume":"5","author":"J Ansell","year":"2007","unstructured":"Ansell J (2007) Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 5(Suppl-1):60\u201364","journal-title":"J Thromb Haemost"},{"key":"2697_CR21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.23139","volume":"87","author":"JI Weitz","year":"2012","unstructured":"Weitz JI (2012) New oral anticoagulants: a view from the laboratory. Am J Haematol. 87:133\u2013136","journal-title":"Am J Haematol."},{"issue":"6","key":"2697_CR22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","volume":"27","author":"AGG Turpie","year":"2007","unstructured":"Turpie AGG (2007) Oral, direct factor Xa inhibitor in development for the prevention and treatment of the thromboembolic diseases. Arterioscler Thromb Vasc Biol 27(6):1238\u20131247","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2697_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-006-5579-4","volume":"21","author":"KA Bauer","year":"2006","unstructured":"Bauer KA (2006) New anticoagulants: anti IIa vs Anti Xa\u2014is one better? J Thromb Thrombolysis 21:67\u201372","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl-1","key":"2697_CR24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1538-7836.2011.04321.x","volume":"9","author":"KA Bauer","year":"2011","unstructured":"Bauer KA (2011) Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 9(Suppl-1):12\u201319","journal-title":"J Thromb Haemost"},{"key":"2697_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5482\/HAMO-12-05-0010","volume":"32","author":"S Konstantinides","year":"2012","unstructured":"Konstantinides S, M\u00fcnzel T (2012) Apixaban. H\u00e4mostaseologie. 32:203\u2013211","journal-title":"H\u00e4mostaseologie."},{"key":"2697_CR26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJ, Zhang D (2011) Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31:478\u2013492","journal-title":"J Thromb Thrombolysis"},{"key":"2697_CR27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1538-7933.2004.00649.x","volume":"2","author":"M Ieko","year":"2004","unstructured":"Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T (2004) Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J Thromb Haemost 2:612\u2013618","journal-title":"J Thromb Haemost"},{"key":"2697_CR28","first-page":"60","volume":"139","author":"H Bounameaux","year":"2009","unstructured":"Bounameaux H (2009) The novel anticoagulants: entering a new era. Swiss Med Wkly. 139:60\u201364","journal-title":"Swiss Med Wkly."}],"container-title":["Archives of Orthopaedic and Trauma Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-017-2697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00402-017-2697-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-017-2697-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T04:03:40Z","timestamp":1494821020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00402-017-2697-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1007\/s00402-017-2697-8","relation":{},"ISSN":["0936-8051","1434-3916"],"issn-type":[{"value":"0936-8051","type":"print"},{"value":"1434-3916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]}}}